China's WuXi Biologics seeks global expansion

Chinese biologics contract manufacturing organization (CMO) Wuxi Biologics (HK: 2269) will continue to invest in capacity expansion in the USA and European Union to speed up its business growth, said the firm’s chief executive Chris Chen at a media conference held in Shanghai this month, reports The Pharma Letter’s local correspondent Wang Fangqing.

The move is under its global dual sourcing strategy, which will allow clients to choose among the facilities in the USA, EU and China.

“Sometimes clients have to change suppliers for logistics reason, and the technology transfer could be risky. With the global presence, we can provide our services consistently,” Mr Chen said.